Companhia Siderúrgica Nacional (SID)

NYQ – Real vaqt narxi. Valyuta: USD

0.94

-0.02 (-1.91%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.95

+0.01 (1.24%)

Bozordan keyin: Jun 26, 2026, 7:56 PM EDT

15.05.2026

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

SID incurs a loss in Q1 as softer steel demand, imports and weather drag revenues, though EBITDA rises and margins improve.

15.05.2026

National Steel Q1 Earnings Call Highlights

National Steel NYSE: SID, the Brazilian steelmaker known as CSN, reported higher first-quarter 2026 adjusted EBITDA despite heavy rainfall, a stronger Brazilian real and continued pressure from steel imports in the early part of the year, executives said on the company's earnings call.

14.05.2026

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

14.05.2026

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.

07.05.2026

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DeepBiology--TRexBio to Present Late-Breaking Data at SID 2026 Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis.

05.05.2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.

12.03.2026

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

14.05.2026

Companhia Siderúrgica Nacional (SID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Companhia Siderúrgica Nacional (SID)

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

National Steel Q1 Earnings Call Highlights

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

National Steel Q1 Earnings Call Highlights

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Search stocks

Companhia Siderúrgica Nacional (SID)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Companhia Siderúrgica Nacional (SID)

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

National Steel Q1 Earnings Call Highlights

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

National Steel Q1 Earnings Miss Estimates on Softer Steel Demand

National Steel Q1 Earnings Call Highlights

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting